Publiczna Szkoła Podstawowa
im. Tadeusza Kościuszki w Błędowie

ul. Stary Rynek 9; 05-620 Błędów
tel: 486680356; bledow@home.pl
Szukaj
Temat
  Zarejestruj się Home  ·  Tematy  ·  Pliki  ·  Twoje konto  ·  Wyślij artykuł  ·  Top 10  
Menu
· Strona główna
· Archiwum artykułów
· Blogi
· Ciekawe strony
· Encyclopedia
· FAQ
· Forum
· Galeria
· Kontakt
· Pliki
· Poleć znajomym
· Statystyki
· Wyślij artykuł
· Zarządzanie kontem

Zawartość
·nasza szkoła
·świetlica szkolna
·Biblioteka i czytelnia
·plan lekcji
·samorząd uczniowski
·klasy
·nauczyciele
·pedagog
·psycholog
·dydaktyka
·absolwenci
·informator trzecioklasisty

Logowanie
Witaj, Anonymous
Pseudonim
Hasło
(Zarejestruj się)
Członkostwo:
Ostatni: iex5avatos
Nowe dzisiaj: 12
Nowe wczoraj: 5
Wszystkie: 19230

Na stronie:
Gości: 154
Użytkowników: 1
Razem: 155

Teraz online:
01: iex5avatos

Publiczna Szkoła Podstawowe im. Tadeusza Kościuszki w Błędowie: Forum

Zespołu Szkół w Błędowie :: Zobacz temat - FDA approves new oral testosterone capsule for treatment of
 FAQFAQ   SzukajSzukaj   GrupyGrupy   ProfilProfil   Zaloguj się, by sprawdzić wiadomościZaloguj się, by sprawdzić wiadomości   ZalogujZaloguj 

FDA approves new oral testosterone capsule for treatment of

 
Napisz nowy temat   Odpowiedz do tematu    Forum Zespołu Szkół w Błędowie Strona Główna -> Gazetka Szkolna
Zobacz poprzedni temat :: Zobacz następny temat  
Autor Wiadomość
goon2019
Newbie
Newbie


Dołączył: May 08, 2019
Posty: 268

PostWysłany: Sob Lip 20, 2019 14:26    Temat postu: FDA approves new oral testosterone capsule for treatment of Odpowiedz z cytatem

FDA approves new oral testosterone capsule for treatment of men

The U.S. Food and Drug Administration today approved Jatenzo (testosterone undecanoate), an oral testosterone capsule to treat men with certain forms of hypogonadism. These men have low testosterone levels due to specific medical conditions, such as genetic disorders like Klinefelter syndrome or tumors that have damaged the pituitary gland. Jatenzo should not be used to treat men with “age-related hypogonadism,” in which testosterone levels decline due to aging, even if these men have symptoms that appear to be related to low testosterone. Jatenzo’s benefits do not outweigh its risks for that use.Testosterone decanoate benefits

“Jatenzo’s oral route of administration provides an important addition to current treatment options available for men with certain hypogonadal conditions who up until now have most commonly been treated with testosterone products that are applied to the skin or injected,” said Hylton V. Joffe, M.D, M.M.Sc., director of the Division of Bone, Reproductive and Urologic Products in the FDA’s Center for Drug Evaluation and Research. “But it’s important to emphasize that this drug should not, like other testosterone treatments, be used to treat older men with ‘age-related hypogonadism.’ The benefits of testosterone therapy, including Jatenzo, have not been established for this use, and Jatenzo’s effects on raising blood pressure can increase the risks of heart attack, stroke and cardiovascular death in this population.”

The efficacy of Jatenzo was demonstrated in a four-month clinical trial involving 166 men with hypogonadism. Study participants initially were given Jatenzo at a dose of 237 mg twice per day, and the dose was adjusted downward or upward to a maximum of 396 mg twice per day on the basis of testosterone levels. Eighty-seven percent of Jatenzo-treated men achieved an average testosterone level within the normal range, which was the primary study endpoint.

Jatenzo contains a boxed warning on its labeling stating that the drug can cause blood pressure to rise, increasing the risk of heart attack, stroke and cardiovascular death. Health care providers should consider a patient’s individual heart disease risks and ensure that blood pressure is adequately controlled before prescribing Jatenzo; they should also periodically monitor patient blood pressure during treatment. Jatenzo is currently one of two testosterone products that have this boxed warning. The FDA is requiring all testosterone product manufacturers to conduct blood pressure postmarketing trials to more clearly address whether these products increase blood pressure.
Common side effects, occurring in more than 2 percent of patients in the Jatenzo clinical trial, included headache, an increase in hematocrit (red blood cell count), a decrease in high-density lipoprotein cholesterol (“good” cholesterol), high blood pressure and nausea. An increase in prostate specific antigen (PSA) was also observed. Patients should have their hematocrit, cholesterol and PSA monitored regularly to check for changes. Those with benign prostate hyperplasia should be monitored for worsening of symptoms.
Powrót do góry
Zobacz profil autora Wyślij prywatną wiadomość
Wyświetl posty z ostatnich:   
Napisz nowy temat   Odpowiedz do tematu    Forum Zespołu Szkół w Błędowie Strona Główna -> Gazetka Szkolna Wszystkie czasy w strefie CET (Europa)
Strona 1 z 1

 
Skocz do:  
Nie możesz pisać nowych tematów
Nie możesz odpowiadać w tematach
Nie możesz zmieniać swoich postów
Nie możesz usuwać swoich postów
Nie możesz głosować w ankietach

Powered by phpBB © 2001, 2005 phpBB Group
Forums ©

 


 

PHP-Nuke Copyright © 2005 by Francisco Burzi. This is free software, and you may redistribute it under the GPL. PHP-Nuke comes with absolutely no warranty, for details, see the license.